Table 8.
Results of the multivariate analysis of prognostic factors on locoregional and distant metastasis-free rates
| Locoregional-free rate | Distant metastasis-free rate | ||||||
|---|---|---|---|---|---|---|---|
| Multivariate analysis | |||||||
| Factor | Level | HR1 | 95% CI | P-value | HR1 | 95% CI | P-value |
| TNM primary | 1 or 2 (52) | 1 | 0.897–10.370 | 0.0740 | |||
| 3 or 4 (35) | 3.051 | ||||||
| TNM LN | 0 or 1 (33) | 1 | 0.531–11.913 | 0.2454 | 2 | ||
| 2 or 3 (54) | 2.514 | ||||||
| Stage | IIB or III (58) | 1 | 1.549–17.347 | 0.0076 | |||
| IV (29) | 5.184 | ||||||
| WHO pathology | I (18) | 1 | 0.074–0.901 | 0.0336 | 3 | ||
| II or III(69) | 0.258 | ||||||
| RT dose primary | <70 (21) | 1 | 0.035–0.972 | 0.0463 | |||
| ≥70 (65) | 0.183 | ||||||
| Total dose of 5-FU | <12,000 (37) | 1 | 0.155–1.012 | 0.0531 | |||
| ≥12,000 (50) | 0.396 | ||||||
| Total dose of CDDP | <300 (38) | 1 | 0.082–0.925 | 0.0369 | |||
| ≥300 (49) | 0.2762 | ||||||
Gender was not incorporated into the multivariate analysis because no events were observed in female.
1
Hazard ratio.
2
N classification was not incorporated into the multivariate analysis because no events were observed in N0 or N1 patients.
3
WHO histology classification was not incorporated into the multivariate analysis because no events were observed in WHO type I patients.